{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:13:54Z","timestamp":1790140434399,"version":"4.0.1"},"reference-count":75,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although omalizumab (anti\u2010IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off\u2010label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of \u201comalizumab\u201d and \u201cimmunotherapy.\u201d Omalizumab has been used in combination with inhalant allergen immunotherapy for the treatment of seasonal allergic rhinitis and comorbid asthma. While there have been no randomized controlled trials evaluating the addition of omalizumab to venom <jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>, several case reports and small patient series have been published on the use of omalizumab with venom <jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>. Omalizumab has been used in conjunction with oral immunotherapy for the treatment of milk, peanut and egg, as well as other foods in multi\u2010allergen protocols. In conclusion, omalizumab used in conjunction with immunotherapy has shown promising results, especially in the reduction of adverse reactions. At this stage, larger, randomized, placebo\u2010controlled trials are needed to better identify those patients who would benefit the most from the addition of omalizumab to immunotherapy, as well as optimal dosing strategies and duration of treatment.<\/jats:p>","DOI":"10.1111\/cea.13084","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T02:22:01Z","timestamp":1515550921000},"page":"232-240","source":"Crossref","is-referenced-by-count":102,"title":["The use of omalizumab in allergen immunotherapy"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-1276","authenticated-orcid":false,"given":"J. A.","family":"Dantzer","sequence":"first","affiliation":[{"name":"Division of Pediatric Allergy and Immunology Department of Pediatrics John Hopkins University School of Medicine Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Wood","sequence":"additional","affiliation":[{"name":"Division of Pediatric Allergy and Immunology Department of Pediatrics John Hopkins University School of Medicine Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4049\/jimmunol.99.5.849","article-title":"Antigenic structure of gamma\u2010E\u2010globulin and reaginic antibody","volume":"99","author":"Ishizaka K","year":"1967","journal-title":"J Immunol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1343"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.04.004"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WOX.0b013e318187a310","article-title":"Anti\u2010immunoglobulin e therapy","volume":"1","author":"Segal M","year":"2008","journal-title":"World Allergy Organ J"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.782391"},{"key":"e_1_2_8_7_1","unstructured":"Xolair\u00aeFull Prescribing Information. Genentech. July 2016 2017.https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf. Accessed September 12 2017."},{"key":"e_1_2_8_8_1","unstructured":"Xolair(R) [package insert]. Genentech Inc. South San Francisco CA 2007. 2017.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/103976s5102lbl.pdf. Accessed September 12 2017."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.07.064"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.4049\/jimmunol.162.9.5624","article-title":"Down\u2010regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti\u2010IgE\u2010infusions is reversible in\u00a0vitro and in\u00a0vivo","volume":"162","author":"Saini SS","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down\u2010regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti\u2010IgE antibody","volume":"158","author":"MacGlashan DW","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00033a020"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta LG","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.03.010"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.2008.S52"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161020-00008"},{"key":"e_1_2_8_18_1","first-page":"341","article-title":"Omalizumab (Xolair) for treatment of asthma","volume":"71","author":"Davydov L","year":"2005","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03490200059007"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.09.034"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908123410702"},{"issue":"8","key":"e_1_2_8_22_1","first-page":"CD001186","article-title":"Injection allergen immunotherapy for asthma","author":"Abramson MJ","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_23_1","first-page":"CD008838","article-title":"Venom immunotherapy for preventing allergic reactions to insect stings","volume":"10","author":"Boyle RJ","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"e_1_2_8_24_1","first-page":"CD001936","article-title":"Allergen injection immunotherapy for seasonal allergic rhinitis","author":"Calderon MA","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.10.031"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2015.08.007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0143"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.01.001"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.004"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.02.006"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.616494"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.01.004"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328364c876"},{"key":"e_1_2_8_34_1","first-page":"241","article-title":"Compliance with an allergen immunotherapy regime","volume":"74","author":"Tinkelman D","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121949"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2009.00900.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.03121.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12098"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.09.036"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.022"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.07.046"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03324.x"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.025"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01604.x"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12948-016-0051-2","article-title":"Dose\u2010dependence of protection from systemic reactions to venom immunotherapy by omalizumab","volume":"14","author":"Boni E","year":"2016","journal-title":"Clin Mol Allergy"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201402700114"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01388.x"},{"key":"e_1_2_8_48_1","first-page":"225","article-title":"Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab","volume":"19","author":"Galera C","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2013.07.004","article-title":"Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome","volume":"1","author":"Silva EN","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_2_8_50_1","first-page":"225","article-title":"Failure of omalizumab treatment after recurrent systemic reactions to bee\u2010venom immunotherapy","volume":"18","author":"Soriano Gomis V","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12997"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-0204"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.582"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90080-L"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)80006-1"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.03.045"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.10.023"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03749.x"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00542.x"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.10.029"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.06.025"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.03.015"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.07.019"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12767"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022613"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.05.039"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.051"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.04.009"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.005"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12567"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.09.046"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.010"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12259"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-10-7"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.028"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009705"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcea.13084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T04:58:33Z","timestamp":1695617913000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.13084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/cea.13084"],"URL":"https:\/\/doi.org\/10.1111\/cea.13084","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]}}}